Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
156M
-
Number of holders
-
85
-
Total 13F shares, excl. options
-
72.6M
-
Shares change
-
+437K
-
Total reported value, excl. options
-
$417M
-
Value change
-
+$2.96M
-
Put/Call ratio
-
0
-
Number of buys
-
39
-
Number of sells
-
-34
-
Price
-
$5.75
Significant Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q3 2023
95 filings reported holding WVE - Wave Life Sciences Ltd. - Ordinary Shares, no par value as of Q3 2023.
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) has 85 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.6M shares
of 156M outstanding shares and own 46.65% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (17.2M shares), M28 Capital Management LP (7.04M shares), MAVERICK CAPITAL LTD (6.59M shares), 683 Capital Management, LLC (5.85M shares), BlackRock Inc. (4.86M shares), Bellevue Group AG (4.49M shares), Kynam Capital Management, LP (3.93M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.79M shares), PRIMECAP MANAGEMENT CO/CA/ (3.78M shares), and Artal Group S.A. (2M shares).
This table shows the top 85 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.